DBV Technologies (DBVT) Competitors $10.80 -0.03 (-0.28%) Closing price 07/11/2025 03:59 PM EasternExtended Trading$11.00 +0.21 (+1.90%) As of 07/11/2025 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DBVT vs. CVAC, CALT, GPCR, HROW, PAHC, ABCL, NTLA, AMPH, WVE, and AUPHShould you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), Harrow (HROW), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), Intellia Therapeutics (NTLA), Amphastar Pharmaceuticals (AMPH), WAVE Life Sciences (WVE), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry. DBV Technologies vs. Its Competitors CureVac Calliditas Therapeutics AB (publ) Structure Therapeutics Harrow Phibro Animal Health AbCellera Biologics Intellia Therapeutics Amphastar Pharmaceuticals WAVE Life Sciences Aurinia Pharmaceuticals DBV Technologies (NASDAQ:DBVT) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation. Is DBVT or CVAC more profitable? CureVac has a net margin of 35.44% compared to DBV Technologies' net margin of -3,249.99%. CureVac's return on equity of 30.89% beat DBV Technologies' return on equity.Company Net Margins Return on Equity Return on Assets DBV Technologies-3,249.99% -278.24% -140.54% CureVac 35.44%30.89%25.54% Does the media prefer DBVT or CVAC? In the previous week, DBV Technologies had 1 more articles in the media than CureVac. MarketBeat recorded 3 mentions for DBV Technologies and 2 mentions for CureVac. CureVac's average media sentiment score of 1.06 beat DBV Technologies' score of 0.75 indicating that CureVac is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CureVac 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, DBVT or CVAC? CureVac has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDBV Technologies$4.15M71.28-$113.92M-$4.92-2.20CureVac$579.18M2.11$175.50M$0.925.93 Do analysts prefer DBVT or CVAC? DBV Technologies presently has a consensus price target of $14.75, indicating a potential upside of 36.57%. CureVac has a consensus price target of $6.83, indicating a potential upside of 25.15%. Given DBV Technologies' stronger consensus rating and higher possible upside, equities analysts plainly believe DBV Technologies is more favorable than CureVac.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DBV Technologies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80CureVac 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Which has more risk & volatility, DBVT or CVAC? DBV Technologies has a beta of -0.59, indicating that its share price is 159% less volatile than the S&P 500. Comparatively, CureVac has a beta of 2.53, indicating that its share price is 153% more volatile than the S&P 500. Do insiders and institutionals have more ownership in DBVT or CVAC? 71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 1.4% of DBV Technologies shares are owned by insiders. Comparatively, 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryCureVac beats DBV Technologies on 10 of the 17 factors compared between the two stocks. Get DBV Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DBVT vs. The Competition Export to ExcelMetricDBV TechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$296.74M$2.97B$5.62B$9.09BDividend YieldN/A2.39%5.24%4.00%P/E Ratio-2.2020.7128.1320.27Price / Sales71.28288.27428.2698.57Price / CashN/A42.8637.4658.16Price / Book7.617.638.045.49Net Income-$113.92M-$55.05M$3.18B$250.45M7 Day Performance-6.40%8.43%3.62%4.79%1 Month Performance11.46%5.42%4.06%7.68%1 Year Performance170.00%2.03%30.01%16.43% DBV Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DBVTDBV Technologies3.9897 of 5 stars$10.80-0.3%$14.75+36.6%+174.4%$296.74M$4.15M-2.2080Gap UpCVACCureVac4.6882 of 5 stars$5.41-0.7%$6.83+26.3%+67.0%$1.22B$579.18M5.88880Positive NewsCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180GPCRStructure Therapeutics2.6096 of 5 stars$18.73-8.0%$76.17+306.7%-55.5%$1.17BN/A-21.53136HROWHarrow2.2083 of 5 stars$31.36-1.2%$61.40+95.8%+47.1%$1.16B$199.61M-56.00180News CoverageAnalyst ForecastPAHCPhibro Animal Health4.0532 of 5 stars$29.90+6.8%$24.40-18.4%+76.0%$1.13B$1.02B38.331,940High Trading VolumeABCLAbCellera Biologics2.4439 of 5 stars$4.03+6.1%$7.50+86.1%+28.1%$1.13B$28.83M-7.20500News CoverageAnalyst RevisionHigh Trading VolumeNTLAIntellia Therapeutics4.3815 of 5 stars$10.25-4.6%$33.37+225.5%-53.2%$1.11B$57.88M-1.96600AMPHAmphastar Pharmaceuticals4.3352 of 5 stars$22.86-1.5%$32.33+41.4%-44.7%$1.09B$731.97M8.282,028WVEWAVE Life Sciences4.5489 of 5 stars$7.06+1.6%$20.50+190.4%+29.8%$1.08B$108.30M-8.40240AUPHAurinia Pharmaceuticals3.0594 of 5 stars$7.47-1.6%$11.50+53.9%+50.2%$1.03B$235.13M26.68300Positive News Related Companies and Tools Related Companies CureVac Alternatives Calliditas Therapeutics AB (publ) Alternatives Structure Therapeutics Alternatives Harrow Alternatives Phibro Animal Health Alternatives AbCellera Biologics Alternatives Intellia Therapeutics Alternatives Amphastar Pharmaceuticals Alternatives WAVE Life Sciences Alternatives Aurinia Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DBVT) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share DBV Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DBVT Stock Alerts